Therapy Areas: Central Nervous System
26 March 2024 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, announced on Monday that it...
26 March 2024 - Brain Trust Bio (BTB), a US-based biotechnology company involved in treatment development for central nervous system (CNS) diseases, announced on Monday that it has received approval t...
25 March 2024 - AI-enabled drug discovery and development company BenevolentAI (Euronext Amsterdam:BAI) on Monday reported positive safety data from the Phase Ia clinical trial of BEN-8744 in healthy ...
25 March 2024 - Science-led biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Ultomiris, a long-acting C5 complement inhibitor, has gained FDA appr...
20 March 2024 - GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company that develops and commercialises gene therapies for retinal neurodegenerative diseases and central nervous system diso...
28 February 2024 - Nuvalent Inc (Nasdaq: NUVL), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has received breakthrough therapy designation (BTD) from the US Food a...